AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?
Pan-Tumor Approach Pays Off So Far
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
You may also be interested in...
The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.
AstraZeneca’s Dato-DXd looks to have so far failed to add a ‘clinically meaningful’ benefit over chemo in the TROPION-Lung01 study, but analysts still expect success for the investigational antibody-drug conjugate.
Glenmark has dropped the price of its trastuzumab biosimilar by over 70% in India. Scrip talks to experts on what that may mean for the competition and also spotlights action around other HER2-directed therapies, including the impending arrival of blockbuster ADC Enhertu.